TRAC team grows again
Cornwall-based regulatory affairs specialist appoints three new members of staff
Grogan takes the role of marketing manager, having relocated from Manchester where she has spent the last seven years in the marketing department of fashion and footwear home retailer JD Williams & Co.
Finlay and May boost TRAC’s Regulatory Affairs team, where they will be working on a range of projects for clients across Europe.
After spending 12 years living and working in Boston, US, Finlay returned to Cornwall in 2005 and graduated with a degree in Biological Science in 2009.
May graduated from Indiana State University in 2007 before relocating to study at the University of Plymouth where he gained a BSc in Human Biosciences.
‘We are delighted to have secured the services of Natalie, Debbie and Mike in the latest part of our development programme. They bring not only experience but also enthusiasm and a real desire to be part of the TRAC success story,’ said TRAC director Sarah Trethowan.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
![What Operation TrialBlazer means for CDMOs and CMC strategy]()
What Operation TrialBlazer means for CDMOs and CMC strategy
The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Manufacturing
![Piramal Pharma Solutions highlights strong performance across more than 200 customer audits]()
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
Regulatory
![FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs]()
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs
GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually